Biovie Inc. (BIVI): Shareholders' Equity
$10.27M
As of 2026-06-30
-12.5%
3-year compound annual growth
+15.3%
5-year compound annual growth
+18.3%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $10.27M | -46.0% | 2026-08-13, Balance as of period end |
| 2025-06-30 | $19.01M | +22.6% | 2026-08-13, Balance as of period end |
| 2024-06-30 | $15.51M | +1.1% | 2025-08-15, Balance as of period end |
| 2023-06-30 | $15.34M | +317.9% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $3.67M | -27.3% | 2023-08-16, Balance as of period end |
| 2021-06-30 | $5.05M | n/m | 2022-09-27, Balance as of period end |
| 2020-06-30 | -$21.50M | n/m | 2021-08-30, Balance as of period end |
| 2019-06-30 | $2.13M | n/m | 2020-08-07, Balance as of period end |
| 2018-06-30 | $111.2K | -90.4% | 2019-09-27, Balance as of period end |
| 2017-06-30 | $1.16M | -39.6% | 2018-10-05, Balance as of period end |
| 2016-06-30 | $1.92M | n/m | 2017-08-24, Balance as of period end |
| 2015-06-30 | -$54.1K | n/m | 2016-09-28, Balance as of period end |
| 2014-06-30 | $171.4K | -65.1% | 2015-10-01, Balance as of period end |
| 2013-06-30 | $490.7K | n/a | 2014-09-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Biovie Inc. (BIVI) | 2026-06-30 | $10.27M | -46.0% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.93M | -42.0% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $7.92M | n/m |
| CytoDyn Inc. (CYDY) | 2026-05-31 | -$109.72M | n/m |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $12.33M | -8.9% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | -$6.64M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $8.54M | -40.3% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $12.45M | +528.5% |
| Cingulate Inc. (CING) | 2025-12-31 | $2.51M | -66.3% |
Compare BIVI, XCUR, ACTU, CYDY side by side · Screen every company in Pharmaceutical Preparations ↗